Blastocyst complementation and interspecies chimeras in gene edited pigs

Yong Ho Choe; Jacob Sorensen; Daniel J. Garry; Mary G. Garry

doi:10.3389/fcell.2022.1065536

Blastocyst complementation and interspecies chimeras in gene edited pigs

Yong Ho Choe, Jacob Sorensen, Daniel J. Garry, Mary G. Garry

Research output: Contribution to journal › Short survey › peer-review

1 Scopus citations

Abstract

The only curative therapy for many endstage diseases is allograft organ transplantation. Due to the limited supply of donor organs, relatively few patients are recipients of a transplanted organ. Therefore, new strategies are warranted to address this unmet need. Using gene editing technologies, somatic cell nuclear transfer and human induced pluripotent stem cell technologies, interspecies chimeric organs have been pursued with promising results. In this review, we highlight the overall technical strategy, the successful early results and the hurdles that need to be addressed in order for these approaches to produce a successful organ that could be transplanted in patients with endstage diseases.

Original language	English (US)
Article number	1065536
Journal	Frontiers in Cell and Developmental Biology
Volume	10
DOIs	https://doi.org/10.3389/fcell.2022.1065536
State	Published - Dec 8 2022

Bibliographical note

Funding Information:
This work was supported by the NIH (HL144582 and HL160476), RMM (101617-DS-003) and DOD. The authors acknowledge the efforts of Cynthia Faraday for figure preparation.

Publisher Copyright:
Copyright © 2022 Choe, Sorensen, Garry and Garry.

Keywords

ETV2
MYF6
Myf5
MyoD
blastocyst complementation
pigs
somatic cell nuclear transfer

Publisher link

10.3389/fcell.2022.1065536

Find It

Find It at U of M Libraries

Cite this

@article{b0866c50d75a4dc1ae792424c53826a9,

title = "Blastocyst complementation and interspecies chimeras in gene edited pigs",

abstract = "The only curative therapy for many endstage diseases is allograft organ transplantation. Due to the limited supply of donor organs, relatively few patients are recipients of a transplanted organ. Therefore, new strategies are warranted to address this unmet need. Using gene editing technologies, somatic cell nuclear transfer and human induced pluripotent stem cell technologies, interspecies chimeric organs have been pursued with promising results. In this review, we highlight the overall technical strategy, the successful early results and the hurdles that need to be addressed in order for these approaches to produce a successful organ that could be transplanted in patients with endstage diseases.",

keywords = "ETV2, MYF6, Myf5, MyoD, blastocyst complementation, pigs, somatic cell nuclear transfer",

author = "Choe, {Yong Ho} and Jacob Sorensen and Garry, {Daniel J.} and Garry, {Mary G.}",

note = "Funding Information: This work was supported by the NIH (HL144582 and HL160476), RMM (101617-DS-003) and DOD. The authors acknowledge the efforts of Cynthia Faraday for figure preparation. Publisher Copyright: Copyright {\textcopyright} 2022 Choe, Sorensen, Garry and Garry.",

year = "2022",

month = dec,

day = "8",

doi = "10.3389/fcell.2022.1065536",

language = "English (US)",

volume = "10",

journal = "Frontiers in Cell and Developmental Biology",

issn = "2296-634X",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Blastocyst complementation and interspecies chimeras in gene edited pigs

AU - Choe, Yong Ho

AU - Sorensen, Jacob

AU - Garry, Daniel J.

AU - Garry, Mary G.

N1 - Funding Information: This work was supported by the NIH (HL144582 and HL160476), RMM (101617-DS-003) and DOD. The authors acknowledge the efforts of Cynthia Faraday for figure preparation. Publisher Copyright: Copyright © 2022 Choe, Sorensen, Garry and Garry.

PY - 2022/12/8

Y1 - 2022/12/8

N2 - The only curative therapy for many endstage diseases is allograft organ transplantation. Due to the limited supply of donor organs, relatively few patients are recipients of a transplanted organ. Therefore, new strategies are warranted to address this unmet need. Using gene editing technologies, somatic cell nuclear transfer and human induced pluripotent stem cell technologies, interspecies chimeric organs have been pursued with promising results. In this review, we highlight the overall technical strategy, the successful early results and the hurdles that need to be addressed in order for these approaches to produce a successful organ that could be transplanted in patients with endstage diseases.

AB - The only curative therapy for many endstage diseases is allograft organ transplantation. Due to the limited supply of donor organs, relatively few patients are recipients of a transplanted organ. Therefore, new strategies are warranted to address this unmet need. Using gene editing technologies, somatic cell nuclear transfer and human induced pluripotent stem cell technologies, interspecies chimeric organs have been pursued with promising results. In this review, we highlight the overall technical strategy, the successful early results and the hurdles that need to be addressed in order for these approaches to produce a successful organ that could be transplanted in patients with endstage diseases.

KW - ETV2

KW - MYF6

KW - Myf5

KW - MyoD

KW - blastocyst complementation

KW - pigs

KW - somatic cell nuclear transfer

UR - http://www.scopus.com/inward/record.url?scp=85144521621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144521621&partnerID=8YFLogxK

U2 - 10.3389/fcell.2022.1065536

DO - 10.3389/fcell.2022.1065536

M3 - Short survey

C2 - 36568986

AN - SCOPUS:85144521621

SN - 2296-634X

VL - 10

JO - Frontiers in Cell and Developmental Biology

JF - Frontiers in Cell and Developmental Biology

M1 - 1065536

ER -

Blastocyst complementation and interspecies chimeras in gene edited pigs

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this